{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:06:30Z","timestamp":1787317590234,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,10,30]],"date-time":"2017-10-30T00:00:00Z","timestamp":1509321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Lions Cancer Research Fund"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lrjournal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.leukres.2017.10.012","type":"journal-article","created":{"date-parts":[[2017,10,28]],"date-time":"2017-10-28T00:47:21Z","timestamp":1509151641000},"page":"41-46","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Towards repositioning of quinacrine for treatment of acute myeloid leukemia \u2013 Promising synergies and in vivo effects"],"prefix":"10.1016","volume":"63","author":[{"given":"Anna","family":"Eriksson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efthymia","family":"Chantzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e5rten","family":"Frykn\u00e4s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Gullbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Nygren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Gustafsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Larsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.leukres.2017.10.012_bib0005","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","article-title":"Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry","volume":"113","author":"Juliusson","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2017.10.012_bib0010","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.1038\/bcj.2015.31","article-title":"Drug screen in patient cells suggests quinacrine to be repositioned for treatment of acute myeloid leukemia","volume":"5","author":"Eriksson","year":"2015","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.leukres.2017.10.012_bib0015","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.26158","article-title":"Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity","volume":"130","author":"Preet","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2017.10.012_bib0020","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.bcp.2016.01.017","article-title":"Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade","volume":"105","author":"Preet","year":"2016","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.leukres.2017.10.012_bib0025","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1067\/msy.2000.107266","article-title":"Interstitial quinacrine for elimination of abnormal tissue; therapy of experimental glioma","volume":"128","author":"Sotelo","year":"2000","journal-title":"Surgery"},{"issue":"2-3","key":"10.1016\/j.leukres.2017.10.012_bib0030","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3727\/096504012X13473664562628","article-title":"Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism","volume":"20","author":"Mohapatra","year":"2012","journal-title":"Oncol. Res."},{"issue":"1-2","key":"10.1016\/j.leukres.2017.10.012_bib0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.curtheres.2012.02.003","article-title":"Quinacrine inhibits cell growth and induces apoptosis in human gastric cancer cell line SGC-7901","volume":"73","author":"Wu","year":"2012","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"9","key":"10.1016\/j.leukres.2017.10.012_bib0040","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-14-0013","article-title":"Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-kappaB, and cell-cycle progression in non-small cell lung cancer","volume":"13","author":"Dermawan","year":"2014","journal-title":"Mol. Cancer Ther."},{"issue":"11","key":"10.1016\/j.leukres.2017.10.012_bib0045","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/bjc.1997.272","article-title":"Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine","volume":"75","author":"de Souza","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2017.10.012_bib0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000313525","article-title":"Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines","volume":"56","author":"Wang","year":"2010","journal-title":"Chemotherapy"},{"key":"10.1016\/j.leukres.2017.10.012_bib0055","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-15-2792","article-title":"Sorafenib and quinacrine target anti-apoptotic protein Mcl-1: a poor prognostic marker in anaplastic thyroid cancer (ATC)","author":"Abdulghani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.leukres.2017.10.012_bib0060","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2217\/fon.09.127","article-title":"New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents","volume":"5","author":"Gurova","year":"2009","journal-title":"Future Oncol."},{"issue":"48","key":"10.1016\/j.leukres.2017.10.012_bib0065","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.0508888102","article-title":"Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors","volume":"102","author":"Gurova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.012_bib0070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000201435","article-title":"Effect of quinacrine, a phospholipase A2 inhibitor on stress and chemically induced gastroduodenal ulcers","volume":"58","author":"Al Moutaery","year":"1997","journal-title":"Digestion"},{"issue":"1","key":"10.1016\/j.leukres.2017.10.012_bib0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.taap.2015.02.005","article-title":"Quinacrine induces apoptosis in human leukemia K562 cells via p38 MAPK-elicited BCL2 down-regulation and suppression of ERK\/c-Jun-mediated BCL2L1 expression","volume":"284","author":"Changchien","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.012_bib0080","doi-asserted-by":"crossref","first-page":"298","DOI":"10.18632\/oncotarget.863","article-title":"DNA-intercalators causing rapid re-expression of methylated and silenced genes in cancer cells","volume":"4","author":"Hossain","year":"2013","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.leukres.2017.10.012_bib0085","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1038\/nprot.2008.114","article-title":"The fluorometric microculture cytotoxicity assay","volume":"3","author":"Lindhagen","year":"2008","journal-title":"Nat. Protoc."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.012_bib0090","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/2211068215598117","article-title":"Ex vivo assessment of drug activity in patient tumor cells as a basis for tailored cancer therapy","volume":"21","author":"Blom","year":"2016","journal-title":"J. Lab. Autom."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.012_bib0095","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/ijc.2910610223","article-title":"Establishment of human acute myelogenous leukemia lines secreting interleukin-1 beta in SCID mice","volume":"61","author":"Giavazzi","year":"1995","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.leukres.2017.10.012_bib0100","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-9-13","article-title":"Beyond DNA binding \u2013 a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers","volume":"9","author":"Ehsanian","year":"2011","journal-title":"Cell Commun. Signal."},{"issue":"1","key":"10.1016\/j.leukres.2017.10.012_bib0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CMR.14.1.114-128.2001","article-title":"Treatment of giardiasis","volume":"14","author":"Gardner","year":"2001","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.leukres.2017.10.012_bib0110","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1471-2334-4-53","article-title":"Pharmacokinetics of quinacrine in the treatment of prion disease","volume":"4","author":"Yung","year":"2004","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.leukres.2017.10.012_bib0115","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"issue":"12","key":"10.1016\/j.leukres.2017.10.012_bib0120","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2017.10.012_bib0125","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1056\/NEJMoa1010222","article-title":"Cytarabine dose for acute myeloid leukemia","volume":"364","author":"Lowenberg","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.leukres.2017.10.012_bib0130","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.23440","article-title":"Does high-dose cytarabine cause cumulative toxicity in patients undergoing consolidation therapy for acute myeloid leukemia?","volume":"88","author":"Wiernik","year":"2013","journal-title":"Am. J. Hematol."},{"issue":"8","key":"10.1016\/j.leukres.2017.10.012_bib0135","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40265-016-0585-0","article-title":"A review in myelodysplastic syndromes and acute myeloid leukaemia","volume":"76","author":"Azacitidine","year":"2016","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.leukres.2017.10.012_bib0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.leukres.2017.10.012_bib0145","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.bbadis.2013.12.009","article-title":"Targeting the nucleolus for cancer intervention","volume":"1842","author":"Quin","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.leukres.2017.10.012_bib0150","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1476-4598-13-116","article-title":"Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia","volume":"13","author":"Haaland","year":"2014","journal-title":"Mol. Cancer"},{"issue":"29","key":"10.1016\/j.leukres.2017.10.012_bib0155","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1038\/onc.2011.48","article-title":"The balance between rRNA and ribosomal protein synthesis up- and downregulates the tumour suppressor p53 in mammalian cells","volume":"30","author":"Donati","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.leukres.2017.10.012_bib0160","first-page":"48","article-title":"Heat shock protein 90 targeting therapy: state of the art and future perspective","volume":"14","author":"Tatokoro","year":"2015","journal-title":"EXCLI J."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305659?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617305659?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,26]],"date-time":"2018-08-26T08:04:49Z","timestamp":1535270689000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617305659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":32,"alternative-id":["S0145212617305659"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.10.012","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Towards repositioning of quinacrine for treatment of acute myeloid leukemia \u2013 Promising synergies and in vivo effects","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}